HC Wainwright Has Optimistic Outlook of SGMO Q3 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Research analysts at HC Wainwright upped their Q3 2025 EPS estimates for shares of Sangamo Therapeutics in a research report issued on Wednesday, May 14th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will post earnings per share of ($0.08) for the quarter, up from their previous estimate of ($0.11). HC Wainwright has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Sangamo Therapeutics' current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Sangamo Therapeutics' FY2025 earnings at ($0.17) EPS, FY2026 earnings at ($0.17) EPS and FY2027 earnings at ($0.04) EPS.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The firm had revenue of $6.44 million for the quarter, compared to the consensus estimate of $7.90 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%.

A number of other research analysts have also commented on SGMO. Royal Bank of Canada restated a "sector perform" rating and set a $2.00 price target on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. Truist Financial cut their target price on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. Finally, Barclays cut their target price on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating for the company in a research report on Wednesday, May 14th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Sangamo Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $4.50.

Sangamo Therapeutics Trading Up 4.4%

Sangamo Therapeutics stock opened at $0.47 on Monday. Sangamo Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.18. The firm has a market capitalization of $107.72 million, a price-to-earnings ratio of -0.63 and a beta of 1.46. The firm has a 50 day simple moving average of $0.73 and a 200 day simple moving average of $1.31.

Institutional Investors Weigh In On Sangamo Therapeutics

Institutional investors have recently made changes to their positions in the company. Point72 Asset Management L.P. bought a new position in Sangamo Therapeutics during the fourth quarter valued at approximately $2,316,000. Schonfeld Strategic Advisors LLC bought a new position in Sangamo Therapeutics during the fourth quarter valued at approximately $1,744,000. GSA Capital Partners LLP lifted its position in Sangamo Therapeutics by 2,962.2% during the first quarter. GSA Capital Partners LLP now owns 966,202 shares of the biopharmaceutical company's stock valued at $634,000 after purchasing an additional 934,649 shares during the period. Acuta Capital Partners LLC bought a new position in Sangamo Therapeutics during the fourth quarter valued at approximately $755,000. Finally, Two Sigma Advisers LP bought a new position in Sangamo Therapeutics during the fourth quarter valued at approximately $722,000. Hedge funds and other institutional investors own 56.93% of the company's stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.